Skip to main content
. 2023 Sep 11;16:17562848231197923. doi: 10.1177/17562848231197923

Table 3.

Infliximab discontinuation rates in retransitioned patients (n = 44).

Infliximab discontinuation Retransitioned due to objective markers (n = 6) Retransitioned due to symptoms only (n = 38)
Infliximab continuation 2 (33.3%) 29 (76.3%)
Overall infliximab discontinuation 4 (66.7%) 9 (23.7%)